首页 > 最新文献

Experimental oncology最新文献

英文 中文
VALIDATION OF A PANEL OF BIOMARKERS ASSOCIATED WITH AGGRESSIVE PHENOTYPE OF ENDOMETRIOID CARCINOMA OF ENDOMETRIUM. 一组与子宫内膜癌侵袭性表型相关的生物标志物的验证。
Q3 Medicine Pub Date : 2022-11-01 DOI: 10.32471/exp-oncology.2312-8852.vol-44-no-3.18513
L G Buchynska, N P Iurchenko, I P Nesina, N M Glushchenko

Aim: To evaluate the prognostic significance of a panel of biomarkers for the identification of a highly malignant molecular subtype of endometrioid carcinoma of the endometrium (ECE).

Materials and methods: The expression of a number of markers (CD24, CD44, E2F1, FOXP3, Her2/neu, p21WAF1/CIP1, p53, β-catenin, vimentin, Е-cadherin, с-Myc, cyclins D1 and Е1) was determined by the immunohistochemical method in the samples of resected tumors of 127 patients with ECE of I-II stage. The Kullback method and the PanelomiX web tool were used to assess the informativeness and identify the aggressive subtype of ECE. The associative relationships of the studied markers were determined using the STRING v11 database.

Results: The study of the prognostic significance of a number of biomarkers in ECE has revealed the informativeness, high specificity and sensitivity (> 95%) of the р53+FOXP3-c-Myc+ phenotype, which is associated with a more aggressive tumor process. Bioinformatics analysis confirmed the correlative relationships between p53, FOXP3 and c-Myc, which are significant prognostic markers associated with cancer progression in ECE patients.

Conclusions: The identified molecular phenotype of ECE (р53+FOXP3-c-Myc+) has differential and prognostic significance and objectively reflects a highly malignant subtype of this form of cancer.

目的:评价一组生物标志物在鉴别子宫内膜高恶性分子亚型子宫内膜样癌(ECE)中的预后意义。材料与方法:采用免疫组化方法检测127例I-II期ECE患者切除肿瘤标本中CD24、CD44、E2F1、FOXP3、Her2/neu、p21WAF1/CIP1、p53、β-catenin、vimentin、Е-cadherin、 - myc、cyclins D1、Е1等标志物的表达。使用Kullback方法和PanelomiX网络工具评估信息量并确定ECE的侵袭性亚型。使用STRING v11数据库确定所研究标记的关联关系。结果:通过对ECE中多个生物标志物的预后意义的研究,揭示了其信息丰富、高特异性和敏感性(> 95%),且其表型与更具有侵袭性的肿瘤过程相关。生物信息学分析证实了p53、FOXP3和c-Myc之间的相关关系,它们是ECE患者癌症进展的重要预后标志物。结论:所鉴定的ECE分子表型(53.53 +FOXP3-c-Myc+)具有鉴别和预后意义,客观反映了该癌的高度恶性亚型。
{"title":"VALIDATION OF A PANEL OF BIOMARKERS ASSOCIATED WITH AGGRESSIVE PHENOTYPE OF ENDOMETRIOID CARCINOMA OF ENDOMETRIUM.","authors":"L G Buchynska,&nbsp;N P Iurchenko,&nbsp;I P Nesina,&nbsp;N M Glushchenko","doi":"10.32471/exp-oncology.2312-8852.vol-44-no-3.18513","DOIUrl":"https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-3.18513","url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the prognostic significance of a panel of biomarkers for the identification of a highly malignant molecular subtype of endometrioid carcinoma of the endometrium (ECE).</p><p><strong>Materials and methods: </strong>The expression of a number of markers (CD24, CD44, E2F1, FOXP3, Her2/neu, p21WAF1/CIP1, p53, β-catenin, vimentin, Е-cadherin, с-Myc, cyclins D1 and Е1) was determined by the immunohistochemical method in the samples of resected tumors of 127 patients with ECE of I-II stage. The Kullback method and the PanelomiX web tool were used to assess the informativeness and identify the aggressive subtype of ECE. The associative relationships of the studied markers were determined using the STRING v11 database.</p><p><strong>Results: </strong>The study of the prognostic significance of a number of biomarkers in ECE has revealed the informativeness, high specificity and sensitivity (> 95%) of the р53+FOXP3-c-Myc+ phenotype, which is associated with a more aggressive tumor process. Bioinformatics analysis confirmed the correlative relationships between p53, FOXP3 and c-Myc, which are significant prognostic markers associated with cancer progression in ECE patients.</p><p><strong>Conclusions: </strong>The identified molecular phenotype of ECE (р53+FOXP3-c-Myc+) has differential and prognostic significance and objectively reflects a highly malignant subtype of this form of cancer.</p>","PeriodicalId":12287,"journal":{"name":"Experimental oncology","volume":"44 3","pages":"234-238"},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40678318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
EFFICACY OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN ADULT BURKITT/BURKITT-LIKE LYMPHOMA: A SYSTEMATIC REVIEW. 自体干细胞移植对成人伯基特/伯基特样淋巴瘤的疗效:系统综述。
Q3 Medicine Pub Date : 2022-11-01 DOI: 10.32471/exp-oncology.2312-8852.vol-44-no-3.18599
U Joshi, R Subedi, G Nepal, S Gyawali, V Agrawal, B S Poudyal, V R Bhatt, Ch R D'Angelo

Background: Burkitt and Burkitt like lymphoma (BL/BLL) are highly proliferative germinal or post-germinal B cell tumors. Few studies have evaluated the impact of autologous stem cell transplantation (ASCT) on disease outcomes.

Aim: We performed a systematic review to analyze the efficacy of ASCT as frontline consolidation and for treatment of relapsed/refractory cases in adult BL/BLL.

Materials and methods: Eligible studies with clear outcome measures on the efficacy of ASCT in adult patients with BL/BLL were identified through systematic search. The overall survival (OS), progression-free survival (PFS), complete response (CR), partial response (PR), and progression/relapse were used to assess the efficacy.

Results: For patients who underwent ASCT in first CR, 5-year PFS and OS ranged between 70-78% and 70-83% respectively. For relapsed/refractory disease, 5-year PFS and OS were 27% and 31%, respectively. Patients undergoing ASCT for chemoresistant disease fared poorly with 3-year OS of 7% vs 37% for chemosensitive disease (p ≤ 0.00001). The overall response rate to ASCT for patients transplanted in first CR ranged between 71% and 93% and was 37% for patients who were transplanted in disease status other than first CR. Disease progression/relapse was observed in 16-29% of the patients transplanted in first CR, and 55% to 60% in relapsed disease.

Conclusion: We found insufficient evidence to support ASCT over chemotherapy alone in the first remission for adult BL/BLL. Evidence supports guidelines recommending ASCT for chemosensitive disease but suggests there is no benefit to ASCT for chemoresistant disease.

背景:伯基特淋巴瘤和类伯基特淋巴瘤(BL/BLL)是高度增殖的生殖性或后生殖性B细胞肿瘤。目的:我们进行了一项系统综述,分析自体干细胞移植作为前线巩固治疗以及治疗成人BL/BLL复发/难治病例的疗效:通过系统检索,确定了对成人BL/BLL患者ASCT疗效有明确结果测量的合格研究。采用总生存期(OS)、无进展生存期(PFS)、完全应答(CR)、部分应答(PR)和进展/复发来评估疗效:首次CR接受ASCT治疗的患者,5年PFS和OS分别为70%-78%和70%-83%。对于复发/难治性疾病,5年PFS和OS分别为27%和31%。因化疗耐药而接受ASCT治疗的患者情况较差,3年OS为7%,而化疗敏感性疾病为37%(P≤0.00001)。首次CR移植患者的ASCT总反应率介于71%和93%之间,首次CR以外疾病状态移植患者的总反应率为37%。在首次CR的移植患者中,16%-29%的患者出现疾病进展/复发,而在复发的患者中,55%-60%的患者出现疾病进展/复发:我们发现,没有足够的证据支持在成人 BL/BLL 首次缓解期进行 ASCT 而非单纯化疗。有证据支持指南推荐对化疗敏感的疾病进行 ASCT,但表明 ASCT 对化疗耐药的疾病没有益处。
{"title":"EFFICACY OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN ADULT BURKITT/BURKITT-LIKE LYMPHOMA: A SYSTEMATIC REVIEW.","authors":"U Joshi, R Subedi, G Nepal, S Gyawali, V Agrawal, B S Poudyal, V R Bhatt, Ch R D'Angelo","doi":"10.32471/exp-oncology.2312-8852.vol-44-no-3.18599","DOIUrl":"10.32471/exp-oncology.2312-8852.vol-44-no-3.18599","url":null,"abstract":"<p><strong>Background: </strong>Burkitt and Burkitt like lymphoma (BL/BLL) are highly proliferative germinal or post-germinal B cell tumors. Few studies have evaluated the impact of autologous stem cell transplantation (ASCT) on disease outcomes.</p><p><strong>Aim: </strong>We performed a systematic review to analyze the efficacy of ASCT as frontline consolidation and for treatment of relapsed/refractory cases in adult BL/BLL.</p><p><strong>Materials and methods: </strong>Eligible studies with clear outcome measures on the efficacy of ASCT in adult patients with BL/BLL were identified through systematic search. The overall survival (OS), progression-free survival (PFS), complete response (CR), partial response (PR), and progression/relapse were used to assess the efficacy.</p><p><strong>Results: </strong>For patients who underwent ASCT in first CR, 5-year PFS and OS ranged between 70-78% and 70-83% respectively. For relapsed/refractory disease, 5-year PFS and OS were 27% and 31%, respectively. Patients undergoing ASCT for chemoresistant disease fared poorly with 3-year OS of 7% vs 37% for chemosensitive disease (p ≤ 0.00001). The overall response rate to ASCT for patients transplanted in first CR ranged between 71% and 93% and was 37% for patients who were transplanted in disease status other than first CR. Disease progression/relapse was observed in 16-29% of the patients transplanted in first CR, and 55% to 60% in relapsed disease.</p><p><strong>Conclusion: </strong>We found insufficient evidence to support ASCT over chemotherapy alone in the first remission for adult BL/BLL. Evidence supports guidelines recommending ASCT for chemosensitive disease but suggests there is no benefit to ASCT for chemoresistant disease.</p>","PeriodicalId":12287,"journal":{"name":"Experimental oncology","volume":"44 3","pages":"190-197"},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40678314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MICRORNA-31 AS A POTENTIAL THERAPEUTIC BIOMARKER FOR ORAL SQUAMOUS CELL CARCINOMA: CURRENT EVIDENCE AND FUTURE PROSPECTS. Microrna-31作为口腔鳞状细胞癌的潜在治疗生物标志物:目前的证据和未来的前景。
Q3 Medicine Pub Date : 2022-11-01 DOI: 10.32471/exp-oncology.2312-8852.vol-44-no-3.18569
M Krishnan, S Babu, S Jayaraman, P Daniel, A Solomon, M Chinnaiyan
{"title":"MICRORNA-31 AS A POTENTIAL THERAPEUTIC BIOMARKER FOR ORAL SQUAMOUS CELL CARCINOMA: CURRENT EVIDENCE AND FUTURE PROSPECTS.","authors":"M Krishnan,&nbsp;S Babu,&nbsp;S Jayaraman,&nbsp;P Daniel,&nbsp;A Solomon,&nbsp;M Chinnaiyan","doi":"10.32471/exp-oncology.2312-8852.vol-44-no-3.18569","DOIUrl":"https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-3.18569","url":null,"abstract":"","PeriodicalId":12287,"journal":{"name":"Experimental oncology","volume":"44 3","pages":"263-264"},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40678316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PRIMARY CUTANEOUS ADENOID CYSTIC CARCINOMA IN THE TRUNK: CASE REPORT AND LITERATURE REVIEW. 躯干原发性皮肤腺样囊性癌:1例报告及文献复习。
Q3 Medicine Pub Date : 2022-08-01 DOI: 10.32471/exp-oncology.2312-8852.vol-44-no-2.18006
M Moreno, Oliveira de, I Czarnobai, Boff Cássia

Primary cystic adenoid skin carcinoma is a rare and poorly documented neoplasm in literature worldwide, with just over 250 reports. This work describes a 52-year-old male patient, with no comorbidities, who presented this neoplasm in nodular format in the posterior thoracic region, associated with localized pain and erythema - symptoms that led him to seek medical help. The clinical findings, differential diagnosis and treatment particularities were reviewed and correlated with the clinical case. The choice of type of surgical treatment was done considering the characteristics of the primary lesion that are associated with a worse prognosis. Despite its rarity, this neoplasm is easily identified through histological examination, the correct choice of treatment and patient follow-up, essential to increase survival. Thus, this work contributes to diminish the scarcity of literature related to this topic, especially the form of treatment employed.

原发性囊性腺样皮肤癌是一种罕见且文献记载不全的肿瘤,在世界范围内仅有250多篇报道。本文描述了一名52岁男性患者,无合并症,在胸后区出现结节状肿瘤,伴有局部疼痛和红斑,这些症状导致他寻求医疗帮助。本文就其临床表现、鉴别诊断及治疗特点进行综述,并与临床病例相联系。手术治疗类型的选择是考虑与预后较差的原发病变相关的特征。尽管罕见,但这种肿瘤很容易通过组织学检查、正确的治疗选择和患者随访来识别,这对提高生存率至关重要。因此,这项工作有助于减少与该主题相关的文献的稀缺性,特别是所采用的治疗形式。
{"title":"PRIMARY CUTANEOUS ADENOID CYSTIC CARCINOMA IN THE TRUNK: CASE REPORT AND LITERATURE REVIEW.","authors":"M Moreno,&nbsp;Oliveira de,&nbsp;I Czarnobai,&nbsp;Boff Cássia","doi":"10.32471/exp-oncology.2312-8852.vol-44-no-2.18006","DOIUrl":"https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-2.18006","url":null,"abstract":"<p><p>Primary cystic adenoid skin carcinoma is a rare and poorly documented neoplasm in literature worldwide, with just over 250 reports. This work describes a 52-year-old male patient, with no comorbidities, who presented this neoplasm in nodular format in the posterior thoracic region, associated with localized pain and erythema - symptoms that led him to seek medical help. The clinical findings, differential diagnosis and treatment particularities were reviewed and correlated with the clinical case. The choice of type of surgical treatment was done considering the characteristics of the primary lesion that are associated with a worse prognosis. Despite its rarity, this neoplasm is easily identified through histological examination, the correct choice of treatment and patient follow-up, essential to increase survival. Thus, this work contributes to diminish the scarcity of literature related to this topic, especially the form of treatment employed.</p>","PeriodicalId":12287,"journal":{"name":"Experimental oncology","volume":"44 2","pages":"174-176"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40707235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
OECI 2022 ONCOLOGY DAYS AND GENERAL ASSEMBLY. Oeci 2022肿瘤学日暨大会。
Q3 Medicine Pub Date : 2022-08-01 DOI: 10.32471/exp-oncology.2312-8852.vol-44-no-2.17945
Ernestas Janulionis

The OECI 2022 Oncology Days and the OECI General Assembly were held in Valencia (Spain) on June 15-17.

OECI 2022 肿瘤学日和OECI大会于6月15日至17日在西班牙瓦伦西亚举行。
{"title":"OECI 2022 ONCOLOGY DAYS AND GENERAL ASSEMBLY.","authors":"Ernestas Janulionis","doi":"10.32471/exp-oncology.2312-8852.vol-44-no-2.17945","DOIUrl":"https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-2.17945","url":null,"abstract":"<p><p>The OECI 2022 Oncology Days and the OECI General Assembly were held in Valencia (Spain) on June 15-17.</p>","PeriodicalId":12287,"journal":{"name":"Experimental oncology","volume":"44 2","pages":"93-94"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40707239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HUMAN MICROBIOTA AND BREAST CANCER. 人类微生物群和乳腺癌。
Q3 Medicine Pub Date : 2022-08-01 DOI: 10.32471/exp-oncology.2312-8852.vol-44-no-2.17855
Yu V Shvets, O O Lykhova, V F Chekhun

Breast cancer is the leading malignancy in women worldwide. To date, much is known about the molecular subtypes of these malignant neoplasms and the mechanisms of drug resistance. Significant success has been achieved in approaches to early diagnosis, which allows identifying the tumor process in the early stages of development. Recently, the study of the influence of the human body microbiota on cancer development and the effectiveness of treatment has become an actively developing field of research. This review presents an analysis of the literature data on this issue.

乳腺癌是全世界妇女的主要恶性肿瘤。迄今为止,对这些恶性肿瘤的分子亚型和耐药性机制了解甚多。在早期诊断方法方面取得了重大成功,可以在发展的早期阶段识别肿瘤进程。近年来,研究人体微生物群对癌症发展和治疗效果的影响已成为一个积极发展的研究领域。本文对这一问题的文献资料进行了分析。
{"title":"HUMAN MICROBIOTA AND BREAST CANCER.","authors":"Yu V Shvets,&nbsp;O O Lykhova,&nbsp;V F Chekhun","doi":"10.32471/exp-oncology.2312-8852.vol-44-no-2.17855","DOIUrl":"https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-2.17855","url":null,"abstract":"<p><p>Breast cancer is the leading malignancy in women worldwide. To date, much is known about the molecular subtypes of these malignant neoplasms and the mechanisms of drug resistance. Significant success has been achieved in approaches to early diagnosis, which allows identifying the tumor process in the early stages of development. Recently, the study of the influence of the human body microbiota on cancer development and the effectiveness of treatment has become an actively developing field of research. This review presents an analysis of the literature data on this issue.</p>","PeriodicalId":12287,"journal":{"name":"Experimental oncology","volume":"44 2","pages":"95-106"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40695912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
THE CHANGES OF NO LEVEL AND RNase ACTIVITY IN TUMOR TISSUE ACCOMPANYING THE PROGRESSION OF PROSTATE CANCER. 前列腺癌进展过程中肿瘤组织NO水平及酶活性的变化。
Q3 Medicine Pub Date : 2022-08-01 DOI: 10.32471/exp-oncology.2312-8852.vol-44-no-2.17785
A P Burlaka, S V Virko, V M Grygorenko, O А Samoylenko, A V Verbinenko, V O Shlyakhovenko

Aim: To assess the inducible NO-synthase activity and the total RNase activity in tissue samples and blood neutrophils of the patients with prostate intraepithelial neoplasia (PIN) and prostate cancer (PCa) of different stages.

Materials and methods: NO level was measured in tumor tissue and neutrophils of patients with PIN and PCa of different stages by electron paramagnetic resonance using the spin traps technology. RNase activity in tumor tissue of patients with PIN and PCa was measured by the method of zymography.

Results: We have found that NO levels in prostate tumor tissue were significantly higher than in the PIN and increased along with the disease progression. Analysis of NO level in neutrophils of the PCa patients demonstrated that the values were not dispersed and did not depend on the stage of disease. NO level in neutrophils of the PCa patients increased manifold as compared with that in healthy donors. At the same time, the RNase activity in the prostate tumor tissue gradually decreased with PCa progression.

Conclusion: Activities of inducible NO-synthase and RNases change significantly with progression of PCa.

目的:探讨不同分期前列腺上皮内瘤变(PIN)和前列腺癌(PCa)患者组织标本和血液中性粒细胞中诱导no合成酶活性、总rna酶活性的变化。材料与方法:采用电子顺磁共振自旋阱技术测定不同分期PIN和PCa患者肿瘤组织及中性粒细胞NO水平。用酶谱法测定PIN和PCa患者肿瘤组织中RNase活性。结果:我们发现前列腺肿瘤组织中NO水平明显高于PIN,且随着疾病进展而升高。对PCa患者中性粒细胞NO水平的分析表明,其值不分散,不依赖于疾病的分期。前列腺癌患者中性粒细胞NO水平较健康供者明显增高。同时随着前列腺癌的进展,前列腺肿瘤组织中RNase活性逐渐降低。结论:随着前列腺癌的进展,诱导no合成酶和rna酶的活性发生显著变化。
{"title":"THE CHANGES OF NO LEVEL AND RNase ACTIVITY IN TUMOR TISSUE ACCOMPANYING THE PROGRESSION OF PROSTATE CANCER.","authors":"A P Burlaka,&nbsp;S V Virko,&nbsp;V M Grygorenko,&nbsp;O А Samoylenko,&nbsp;A V Verbinenko,&nbsp;V O Shlyakhovenko","doi":"10.32471/exp-oncology.2312-8852.vol-44-no-2.17785","DOIUrl":"https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-2.17785","url":null,"abstract":"<p><strong>Aim: </strong>To assess the inducible NO-synthase activity and the total RNase activity in tissue samples and blood neutrophils of the patients with prostate intraepithelial neoplasia (PIN) and prostate cancer (PCa) of different stages.</p><p><strong>Materials and methods: </strong>NO level was measured in tumor tissue and neutrophils of patients with PIN and PCa of different stages by electron paramagnetic resonance using the spin traps technology. RNase activity in tumor tissue of patients with PIN and PCa was measured by the method of zymography.</p><p><strong>Results: </strong>We have found that NO levels in prostate tumor tissue were significantly higher than in the PIN and increased along with the disease progression. Analysis of NO level in neutrophils of the PCa patients demonstrated that the values were not dispersed and did not depend on the stage of disease. NO level in neutrophils of the PCa patients increased manifold as compared with that in healthy donors. At the same time, the RNase activity in the prostate tumor tissue gradually decreased with PCa progression.</p><p><strong>Conclusion: </strong>Activities of inducible NO-synthase and RNases change significantly with progression of PCa.</p>","PeriodicalId":12287,"journal":{"name":"Experimental oncology","volume":"44 2","pages":"159-162"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40695915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
POLYAMINES AS NEW POTENTIAL BIOMARKERS FOR DIFFERENTIAL DIAGNOSIS OF PROSTATE CANCER AND ESTIMATION OF ITS AGGRESSIVENESS. 多胺作为前列腺癌鉴别诊断和评估其侵袭性的新的潜在生物标志物。
Q3 Medicine Pub Date : 2022-08-01 DOI: 10.32471/exp-oncology.2312-8852.vol-44-no-2.17758
S P Zaletok, O O Klenov, V V Bentrad, M P Prylutskyi, Yu V Vitruk, E O Stakhovsky, A V Timoshenko

Background: Prostate cancer (PCa) is one of the most common malignancies in older men. The study of tissue markers of PCa can provide information about the state of proliferation and apoptosis in tumors, the susceptibility of tumor cells to metastasis and the mechanisms of resistance to therapy, which, in turn, can help predict the course of the disease and develop personalized treatment. Polyamines (PAs) spermine, spermidine, putrescine are of particular interest in terms of PCa tissue markers.

Aim: To investigate the levels of basic and acetylated forms of PAs in the postoperative samples of malignant and benign tumors of the human prostate and evaluate the possibility of their use for differential diagnosis and assessment of the PCa aggressiveness.

Object and methods: 57 postoperative tumor samples from patients with prostate adenocarcinoma of different Gleason score (GS) and clinical stage (T1-T4) and 20 samples of tumors from patients with benign prostate hyperplasia (BPH) were studied. The content of PAs was determined by high performance liquid chromatography.

Results: Among the studied PAs, the most significant difference between PCa and BPH was observed for spermine (Spm). The level of Spm in PCa samples was 16 times lower than in BPH samples (p < 0.01). We did not find a significant dependence of PAs levels, including Spm, on the clinical stage. The association between the Spm level and the GS was established. The indolent (GS6) tumors were characterized by the highest Spm level while in the most aggressive (GS9 and GS10) tumors Spm content was the lowest.

Conclusions: A sharp decrease in Spm levels is probably a characteristic feature of prostate malignant tumors. The obtained results indicate an association of Spm levels in tumors with the GS. This may indicate Spm involvement in the formation of the aggressiveness of PCa. The results of the study can be further used for differential diagnosis of prostate tumors and for assessing the aggressiveness of PCa.

背景:前列腺癌是老年男性最常见的恶性肿瘤之一。通过对前列腺癌组织标志物的研究,可以了解肿瘤的增殖和凋亡状态、肿瘤细胞的转移易感性和耐药机制,从而预测疾病的发展进程,制定个性化的治疗方案。多胺(PAs)精胺,亚精胺,腐胺是特别感兴趣的PCa组织标志物。目的:探讨人前列腺恶性肿瘤和良性肿瘤术后标本中碱性和乙酰化形式PAs的水平,并评价其用于鉴别诊断和评估前列腺癌侵袭性的可能性。目的与方法:选取不同Gleason评分(GS)、临床分期(t1 ~ t4)的前列腺腺癌患者术后肿瘤标本57例,良性前列腺增生(BPH)患者术后肿瘤标本20例。采用高效液相色谱法测定PAs的含量。结果:在所研究的PAs中,精胺(Spm)在PCa和BPH之间的差异最为显著。结论:前列腺癌标本中Spm水平的急剧下降可能是前列腺恶性肿瘤的一个特征。所得结果表明肿瘤中Spm水平与GS有关。这可能表明Spm参与了前列腺癌侵袭性的形成。本研究结果可进一步用于前列腺肿瘤的鉴别诊断和前列腺癌侵袭性的评估。
{"title":"POLYAMINES AS NEW POTENTIAL BIOMARKERS FOR DIFFERENTIAL DIAGNOSIS OF PROSTATE CANCER AND ESTIMATION OF ITS AGGRESSIVENESS.","authors":"S P Zaletok,&nbsp;O O Klenov,&nbsp;V V Bentrad,&nbsp;M P Prylutskyi,&nbsp;Yu V Vitruk,&nbsp;E O Stakhovsky,&nbsp;A V Timoshenko","doi":"10.32471/exp-oncology.2312-8852.vol-44-no-2.17758","DOIUrl":"https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-2.17758","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer (PCa) is one of the most common malignancies in older men. The study of tissue markers of PCa can provide information about the state of proliferation and apoptosis in tumors, the susceptibility of tumor cells to metastasis and the mechanisms of resistance to therapy, which, in turn, can help predict the course of the disease and develop personalized treatment. Polyamines (PAs) spermine, spermidine, putrescine are of particular interest in terms of PCa tissue markers.</p><p><strong>Aim: </strong>To investigate the levels of basic and acetylated forms of PAs in the postoperative samples of malignant and benign tumors of the human prostate and evaluate the possibility of their use for differential diagnosis and assessment of the PCa aggressiveness.</p><p><strong>Object and methods: </strong>57 postoperative tumor samples from patients with prostate adenocarcinoma of different Gleason score (GS) and clinical stage (T1-T4) and 20 samples of tumors from patients with benign prostate hyperplasia (BPH) were studied. The content of PAs was determined by high performance liquid chromatography.</p><p><strong>Results: </strong>Among the studied PAs, the most significant difference between PCa and BPH was observed for spermine (Spm). The level of Spm in PCa samples was 16 times lower than in BPH samples (p < 0.01). We did not find a significant dependence of PAs levels, including Spm, on the clinical stage. The association between the Spm level and the GS was established. The indolent (GS6) tumors were characterized by the highest Spm level while in the most aggressive (GS9 and GS10) tumors Spm content was the lowest.</p><p><strong>Conclusions: </strong>A sharp decrease in Spm levels is probably a characteristic feature of prostate malignant tumors. The obtained results indicate an association of Spm levels in tumors with the GS. This may indicate Spm involvement in the formation of the aggressiveness of PCa. The results of the study can be further used for differential diagnosis of prostate tumors and for assessing the aggressiveness of PCa.</p>","PeriodicalId":12287,"journal":{"name":"Experimental oncology","volume":"44 2","pages":"148-154"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40695916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
АNTIMETASTATIC EFFECT OF B. SUBTILIS IMV B-7724 LECTIN OBSERVED IN LEWIS LUNG CARCINOMA MODEL. Аntimetastatic枯草芽孢杆菌imv b-7724凝集素在lewis肺癌模型中的作用。
Q3 Medicine Pub Date : 2022-08-01 DOI: 10.32471/exp-oncology.2312-8852.vol-44-no-2.17914
N I Fedosova, T V Symchych, N L Cheremshenko, A V Chumak, E V Koval, О М Karaman, I M Voyejkova

Aim: To study the antitumor and antimetastatic effects of B. subtilis IMV B-7724 lectin used in neoadjuvant and adjuvant settings in vivo.

Materials and methods: Studies were performed on C57Bl/6J mice; Lewis lung carcinoma (LLC) was used as an experimental tumor. В. subtilis ІМV В-7724 lectin was administered to tumor-bearing mice or to mice which underwent surgical resection of the primary tumor. The lectin was injected subcutaneously, 10 times, at a single dose of 5 or 1 mg/kg of body weight. The standard indicators of tumor growth and metastasis were evaluated.

Results: Independently of the application settings, the lectin at a dose of 1 mg/kg of b.w. caused more pronounced effect than at a dose of 5 mg/kg of b.w. The administration of B. subtilis IMV B-7724 lectin to the mice with LLC in neoadjuvant setting did not cause notable antitumor effect but led to a significant decrease in the number and volume of lung metastases. The lectin administration in adjuvant setting significantly inhibited metastasis: the metastasis inhibition index reached 63.0% and 100% in the mice treated with the lectin at a dose of 5 mg/kg and 1 mg/kg respectively. The mean survival time of the treated animals significantly increased.

Conclusion: A pronounced antimetastatic effect of B. subtilis IMV B-7724 lectin administered in an adjuvant setting was demonstrated.

目的:研究枯草芽孢杆菌IMV B-7724凝集素在体内新佐剂和佐剂中的抗肿瘤和抗转移作用。材料与方法:C57Bl/6J小鼠;Lewis肺癌(LLC)作为实验肿瘤。В。枯草杆菌ІМV В-7724凝集素给予荷瘤小鼠或手术切除原发肿瘤的小鼠。将凝集素皮下注射10次,单次剂量为5或1 mg/kg体重。评估肿瘤生长和转移的标准指标。结果:与应用环境无关,枯草芽孢杆菌IMV B-7724凝集素在1 mg/kg体重下的作用比5 mg/kg体重下的作用更明显。在新辅助环境下,枯草芽孢杆菌IMV B-7724凝集素对LLC小鼠的抗肿瘤作用不显著,但导致肺转移瘤的数量和体积显著减少。在佐剂环境下给予凝集素显著抑制转移:5 mg/kg和1 mg/kg剂量的凝集素对小鼠的转移抑制指数分别达到63.0%和100%。治疗组动物的平均生存时间明显延长。结论:枯草芽孢杆菌IMV B-7724凝集素在佐剂环境中具有明显的抗转移作用。
{"title":"АNTIMETASTATIC EFFECT OF B. SUBTILIS IMV B-7724 LECTIN OBSERVED IN LEWIS LUNG CARCINOMA MODEL.","authors":"N I Fedosova,&nbsp;T V Symchych,&nbsp;N L Cheremshenko,&nbsp;A V Chumak,&nbsp;E V Koval,&nbsp;О М Karaman,&nbsp;I M Voyejkova","doi":"10.32471/exp-oncology.2312-8852.vol-44-no-2.17914","DOIUrl":"https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-2.17914","url":null,"abstract":"<p><strong>Aim: </strong>To study the antitumor and antimetastatic effects of B. subtilis IMV B-7724 lectin used in neoadjuvant and adjuvant settings in vivo.</p><p><strong>Materials and methods: </strong>Studies were performed on C57Bl/6J mice; Lewis lung carcinoma (LLC) was used as an experimental tumor. В. subtilis ІМV В-7724 lectin was administered to tumor-bearing mice or to mice which underwent surgical resection of the primary tumor. The lectin was injected subcutaneously, 10 times, at a single dose of 5 or 1 mg/kg of body weight. The standard indicators of tumor growth and metastasis were evaluated.</p><p><strong>Results: </strong>Independently of the application settings, the lectin at a dose of 1 mg/kg of b.w. caused more pronounced effect than at a dose of 5 mg/kg of b.w. The administration of B. subtilis IMV B-7724 lectin to the mice with LLC in neoadjuvant setting did not cause notable antitumor effect but led to a significant decrease in the number and volume of lung metastases. The lectin administration in adjuvant setting significantly inhibited metastasis: the metastasis inhibition index reached 63.0% and 100% in the mice treated with the lectin at a dose of 5 mg/kg and 1 mg/kg respectively. The mean survival time of the treated animals significantly increased.</p><p><strong>Conclusion: </strong>A pronounced antimetastatic effect of B. subtilis IMV B-7724 lectin administered in an adjuvant setting was demonstrated.</p>","PeriodicalId":12287,"journal":{"name":"Experimental oncology","volume":"44 2","pages":"155-158"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40695472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
EXPRESSION OF miRNA AS PROGNOSTIC MARKERS OF RENAL CELL CARCINOMA COURSE. miRNA的表达作为肾细胞癌病程的预后标志物。
Q3 Medicine Pub Date : 2022-08-01 DOI: 10.32471/exp-oncology.2312-8852.vol-44-no-2.17883
Yu Vitruk, T Borikun, O Rossylna, T Zadvornyi, S Semko, O Voylenko, O Stakhovsky, A Shipko, E Stakhovsky

Renal cell carcinoma (RCC) is one of the most common solid tumors in adults. There is a lack of reliable prognostic and predictive biomarkers for RCC course. Dysregulation of miRNAs expression has been reported to be involved in RCC progression. However, the data on miRNAs expression patterns in tumors are controversial.

Aim: To investigate the expression and clinical significance of miR-99b, -144, -155, -210, -222, -302а, -377 in RCC ex vivo.

Materials and methods: Retrospective analysis of the expression levels of miRNAs -99b, -144, -155, -210, -222, -302а, -377 in tumor tissue of 126 patients with clear cell RCC was performed using quantitative polymerase chain reaction.

Results: Overexpression of miR-99b, -222, -302a and low levels of miR-155 in RCC tissues were significantly associated with advanced tumor stage (p < 0.05). In majority of patients with distant metastases (> 60%), high levels of miR-99b and 377 were detected (p < 0.05). High/low miR-99b, -144, -155, -210, -222, and -302a ratio was significantly associated with Fuhrman grade of tumors.

Conclusion: Aberrant expression of miR-99b, -144, -155, -210, -222, -302а, -377 is strongly associated with advanced RCC, and panel of these miRNAs may be a useful prognostic marker for RCC course.

肾细胞癌(RCC)是成人最常见的实体肿瘤之一。目前缺乏可靠的预后和预测RCC病程的生物标志物。据报道,mirna表达的失调与RCC的进展有关。然而,关于肿瘤中miRNAs表达模式的数据存在争议。目的:探讨miR-99b、-144、-155、-210、-222、-302、-377在离体RCC中的表达及临床意义。材料与方法:采用定量聚合酶链反应,回顾性分析126例透明细胞RCC患者肿瘤组织中miRNAs -99b、-144、-155、-210、-222、-302、-377的表达水平。结果:RCC组织中miR-99b、-222、-302a过表达和miR-155低表达与肿瘤分期晚期有显著相关性(p < 0.05)。在大多数远处转移患者(> 60%)中,检测到高水平的miR-99b和377 (p < 0.05)。高/低miR-99b、-144、-155、-210、-222和-302a比值与肿瘤的Fuhrman分级显著相关。结论:miR-99b、-144、-155、-210、-222、-302、-377的异常表达与晚期RCC密切相关,这些mirna的表达水平可能是预测RCC病程的有效指标。
{"title":"EXPRESSION OF miRNA AS PROGNOSTIC MARKERS OF RENAL CELL CARCINOMA COURSE.","authors":"Yu Vitruk,&nbsp;T Borikun,&nbsp;O Rossylna,&nbsp;T Zadvornyi,&nbsp;S Semko,&nbsp;O Voylenko,&nbsp;O Stakhovsky,&nbsp;A Shipko,&nbsp;E Stakhovsky","doi":"10.32471/exp-oncology.2312-8852.vol-44-no-2.17883","DOIUrl":"https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-2.17883","url":null,"abstract":"<p><p>Renal cell carcinoma (RCC) is one of the most common solid tumors in adults. There is a lack of reliable prognostic and predictive biomarkers for RCC course. Dysregulation of miRNAs expression has been reported to be involved in RCC progression. However, the data on miRNAs expression patterns in tumors are controversial.</p><p><strong>Aim: </strong>To investigate the expression and clinical significance of miR-99b, -144, -155, -210, -222, -302а, -377 in RCC ex vivo.</p><p><strong>Materials and methods: </strong>Retrospective analysis of the expression levels of miRNAs -99b, -144, -155, -210, -222, -302а, -377 in tumor tissue of 126 patients with clear cell RCC was performed using quantitative polymerase chain reaction.</p><p><strong>Results: </strong>Overexpression of miR-99b, -222, -302a and low levels of miR-155 in RCC tissues were significantly associated with advanced tumor stage (p < 0.05). In majority of patients with distant metastases (> 60%), high levels of miR-99b and 377 were detected (p < 0.05). High/low miR-99b, -144, -155, -210, -222, and -302a ratio was significantly associated with Fuhrman grade of tumors.</p><p><strong>Conclusion: </strong>Aberrant expression of miR-99b, -144, -155, -210, -222, -302а, -377 is strongly associated with advanced RCC, and panel of these miRNAs may be a useful prognostic marker for RCC course.</p>","PeriodicalId":12287,"journal":{"name":"Experimental oncology","volume":"44 2","pages":"132-136"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40695474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Experimental oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1